Chloropromazine Sulfoxide

Chloropromazine Sulfoxide

SCHEMBL1155596

CN(C)CCCN1c2ccccc2[S+]([O-])c2ccc(Cl)cc21

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.62
CYP1A2 P05177 7/20 0.62
DRD2 P14416 6/20 0.62
SLC6A4 P31645 6/20 0.62
HTR1A P08908 5/20 0.62
KMT2A Q03164 5/20 0.62
CHRM1 P11229 5/20 0.62
ADRA2B P18089 5/20 0.62
ADRA2C P18825 5/20 0.62
CHRM3 P20309 5/20 0.62
SLC6A2 P23975 5/20 0.62
HTR2A P28223 5/20 0.62
HTR2C P28335 5/20 0.62
ADRA1A P35348 5/20 0.62
HRH1 P35367 5/20 0.62
DRD3 P35462 5/20 0.62
OPRK1 P41145 5/20 0.62
KCNH2 Q12809 5/20 0.62
TP53 P04637 4/20 0.62
MEN1 O00255 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloropromazine Sulfoxide SCHEMBL31540233 1.00 CYP2D6 (0.62) CYP2D6CYP1A2DRD2SLC6A4HTR1A
Chloropromazine Sulfoxide SCHEMBL30463300 1.00 CYP2D6 (0.62) CYP2D6CYP1A2DRD2SLC6A4HTR1A
Chloropromazine Sulfoxide SCHEMBL9724483 0.99 LMNA (0.63) CYP2D6CYP1A2DRD2SLC6A4HTR1A
SCHEMBL10925157 0.95 CYP2D6 (0.62) CYP2D6CYP1A2DRD2SLC6A4HTR1A
SCHEMBL11077473 0.83 HTR2A (0.47) CYP2D6CYP1A2DRD2SLC6A4HTR1A
SCHEMBL9570366 0.82 MEN1 (0.42) CYP2D6CYP1A2DRD2SLC6A4HTR1A
Bromide SCHEMBL8869261 0.81 MEN1 (0.41) CYP2D6CYP1A2DRD2SLC6A4HTR1A
SCHEMBL9570344 0.81 DRD2 (0.42) CYP2D6CYP1A2DRD2SLC6A4HTR1A
SCHEMBL18752073 0.81 DRD2 (0.63) CYP2D6CYP1A2DRD2SLC6A4HTR1A
Bromide SCHEMBL8870578 0.80 DRD2 (0.41) CYP2D6CYP1A2DRD2SLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174700-A1 LAYERED SUPERHYDROPHILIC TI-CU-MOFS, PREPARATION METHOD AND USE THEREOF ZHEJIANG SHUREN UNIVERSITY (CN) 2024-05-30 US claimed
US-11766441-B2 Oral liquid compositions including chlorpromazine Genus Lifesciences Inc. (US) 2023-09-26 US claimed
WO-2023147730-A1 LAYERED SUPER-HYDROPHILIC TI-CU-MOFS AND PREPARATION METHOD AND APPLICATION THEREOF 浙江树人学院 2023-08-10 WO claimed
CN-113109474-B Method for detecting sedative drug metabolism residues in animal tissues 吉林省农业科学院 2023-08-01 CN claimed
CN-114479108-B Layered super-hydrophilic Ti-Cu-MOFs and preparation method and application thereof 浙江树人学院 2023-03-24 CN claimed
US-11426413-B2 Oral liquid compositions including chlorpromazine Genus Lifesciences Inc. (US) 2022-08-30 US claimed
CN-114479108-A Layered super-hydrophilic Ti-Cu-MOFs and preparation method and application thereof 浙江树人学院 2022-05-13 CN claimed
US-20220096489-A1 ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE FIFTH THIRD BANK, NATIONAL ASSOCIATION 2022-03-31 US claimed
US-20220096488-A1 ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE FIFTH THIRD BANK, NATIONAL ASSOCIATION 2022-03-31 US claimed
US-11071739-B1 Oral liquid compositions including chlorpromazine Genus Lifesciences Inc. (US) 2021-07-27 US claimed
CN-113109474-A Method for detecting metabolic residues of sedative drugs in animal tissues 吉林省农业科学院 2021-07-13 CN claimed
EP-0125654-B1 PROCESS FOR THE PREPARATION OF ESPECIALLY PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING A SULFOXIDE GROUP ZAMBON S.p.A. (IT) 1987-07-29 EP claimed
US-4628087-A Process for the preparation of pharmacologically active compounds containing a sulfoxide group ZAMBON S.P.A. (IT) 1986-12-09 US claimed
US-4407800-A TRYPANOCIDES UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1983-10-04 US claimed
EP-0082203-A1 USE OF CALMODULIN BINDING DRUGS IN UTERUS TO PREVENT PREGNANCY THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1983-06-29 EP claimed
WO-1983000086-A1 USE OF CALMODULIN BINDING DRUGS IN UTERUS TO PREVENT PREGNANCY UNIV GEORGIA RES FOUND (US) 1983-01-20 WO claimed
US-12583877-B2 Layered superhydrophilic Ti—Cu-MOFs, preparation method and use thereof ZHEJIANG SHUREN UNIVERSITY (CN) 2026-03-24 US disclosed
US-20240174700-A1 LAYERED SUPERHYDROPHILIC TI-CU-MOFS, PREPARATION METHOD AND USE THEREOF ZHEJIANG SHUREN UNIVERSITY (CN) 2024-05-30 US disclosed
WO-1983000086-A1 USE OF CALMODULIN BINDING DRUGS IN UTERUS TO PREVENT PREGNANCY UNIV GEORGIA RES FOUND (US) 1983-01-20 WO disclosed
US-3976763-A Chlorpromazine assay HOFFMANN-LA ROCHE INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11426413-B2 Oral liquid compositions including chlorpromazine WIZ, CPNE4, CYP3A5 CYP2D6 17/4885CYP1A2 189/4885DRD2 371/4885
US-20220096488-A1 ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE WIZ, CPNE4, CYP3A5 CYP2D6 17/4885CYP1A2 189/4885DRD2 371/4885
US-11071739-B1 Oral liquid compositions including chlorpromazine WIZ, CPNE4, CYP3A5 CYP2D6 17/4885CYP1A2 189/4885DRD2 371/4885
US-11766441-B2 Oral liquid compositions including chlorpromazine WIZ, CPNE4, CYP3A5 CYP2D6 17/4885CYP1A2 189/4885DRD2 371/4885
US-12583877-B2 Layered superhydrophilic Ti—Cu-MOFs, preparation method and use thereof SLC7A1, MAOB, TH CYP2D6 291/4885CYP1A2 124/4885DRD2 1835/4885
US-20220096489-A1 ORAL LIQUID COMPOSITIONS INCLUDING CHLORPROMAZINE WIZ, CPNE4, CYP3A5 CYP2D6 17/4885CYP1A2 189/4885DRD2 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.